Cargando…
Trace Amine Associate Receptor 1 (TAAR1) as a New Target for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease
Worldwide, approximately 27 million people are affected by Alzheimer’s disease (AD). AD pathophysiology is believed to be caused by the deposition of the β-amyloid peptide (Aβ). Aβ can reduce long-term potentiation (LTP), a form of synaptic plasticity that is closely associated with learning and mem...
Autores principales: | Leo, Damiana, Targa, Giorgia, Espinoza, Stefano, Villers, Agnès, Gainetdinov, Raul R., Ris, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318502/ https://www.ncbi.nlm.nih.gov/pubmed/35887159 http://dx.doi.org/10.3390/ijms23147811 |
Ejemplares similares
-
Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
por: Espinoza, Stefano, et al.
Publicado: (2018) -
Improved cognitive performance in trace amine-associated receptor 5 (TAAR5) knock-out mice
por: Maggi, Silvia, et al.
Publicado: (2022) -
Deregulation of Trace Amine-Associated Receptors (TAAR) Expression and Signaling Mode in Melanoma
por: Vaganova, Anastasia N., et al.
Publicado: (2022) -
Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors
por: Glyakina, Anna V., et al.
Publicado: (2021) -
Discovery of Novel Trace Amine-Associated Receptor 5 (TAAR5) Antagonists Using a Deep Convolutional Neural Network
por: Bon, Carlotta, et al.
Publicado: (2022)